MX2023004933A - Proteinas de fusion de ace2 y usos de las mismas. - Google Patents

Proteinas de fusion de ace2 y usos de las mismas.

Info

Publication number
MX2023004933A
MX2023004933A MX2023004933A MX2023004933A MX2023004933A MX 2023004933 A MX2023004933 A MX 2023004933A MX 2023004933 A MX2023004933 A MX 2023004933A MX 2023004933 A MX2023004933 A MX 2023004933A MX 2023004933 A MX2023004933 A MX 2023004933A
Authority
MX
Mexico
Prior art keywords
fusion proteins
ace2
ace2 fusion
coronaviruses
cov
Prior art date
Application number
MX2023004933A
Other languages
English (en)
Inventor
Carsten Brockmeyer
Alwin Reiter
Florian Wolschin
Original Assignee
Formycon Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Formycon Ag filed Critical Formycon Ag
Publication of MX2023004933A publication Critical patent/MX2023004933A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a proteínas de fusión de ACE2 con Fc de IgG y al uso médico de estas proteínas de fusión, en particular en la prevención o tratamiento de infecciones con coronavirus tal como SARS-CoV-2.
MX2023004933A 2020-10-29 2021-10-29 Proteinas de fusion de ace2 y usos de las mismas. MX2023004933A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20204774 2020-10-29
EP20210297 2020-11-27
EP21164684 2021-03-24
EP21170519 2021-04-26
PCT/EP2021/080130 WO2022090469A2 (en) 2020-10-29 2021-10-29 Ace2 fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2023004933A true MX2023004933A (es) 2023-06-06

Family

ID=78528930

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004933A MX2023004933A (es) 2020-10-29 2021-10-29 Proteinas de fusion de ace2 y usos de las mismas.

Country Status (8)

Country Link
US (1) US20240018499A1 (es)
EP (1) EP4204091A2 (es)
JP (1) JP2023547239A (es)
KR (1) KR20230093483A (es)
AU (1) AU2021367988A1 (es)
CA (1) CA3193930A1 (es)
MX (1) MX2023004933A (es)
WO (1) WO2022090469A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4377452A2 (en) 2021-07-30 2024-06-05 Formycon AG Ace2 fusion proteins and uses thereof
EP4331571A1 (en) 2022-09-02 2024-03-06 Formycon AG Formulations of ace2-igm fusion proteins
EP4386084A1 (en) 2022-12-14 2024-06-19 Formycon AG Improved ace2 fusion proteins

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
ATE240395T1 (de) 1994-03-29 2003-05-15 Celltech Therapeutics Ltd Antikörper gegen e-selektin
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
SI1562972T1 (sl) 2002-10-15 2010-12-31 Facet Biotech Corp ALTERACIJA FcRn VEZANIH AFINITET ALI SERUMSKIH RAZPOLOVNIH DOB ANTITELESC Z MUTAGENEZO
WO2005032487A2 (en) 2003-10-06 2005-04-14 The Brigham And Women's Hospital, Inc. Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus
KR101027427B1 (ko) 2004-11-12 2011-04-11 젠코어 인코포레이티드 ＦcRn에 대하여 증가된 결합력을 갖는 Ｆc 변이체
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
SI2235059T1 (sl) 2007-12-26 2015-06-30 Xencor, Inc. Fc variante s spremenjeno vezjo na fcrn
WO2010033279A2 (en) 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
EA201890907A1 (ru) * 2009-11-30 2020-04-30 Янссен Байотек, Инк. МУТИРОВАННЫЕ Fc АНТИТЕЛА С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ
MX339809B (es) 2010-05-27 2016-06-09 Merck Sharp & Dohme Corp * Metodo para preparar anticuerpos con propiedades mejoradas.
MX354359B (es) 2011-03-29 2018-02-28 Roche Glycart Ag Variantes de fragmento cristalizable (fc) de los anticuerpos.
KR20140068861A (ko) * 2011-06-28 2014-06-09 인히브릭스 엘엘씨 Wap 도메인 융합 폴리펩티드 및 이의 이용 방법
MX360368B (es) 2012-04-27 2018-10-29 Bioatla Llc Regiones de anticuerpo modificado y sus usos.
EP3743441A1 (en) * 2018-01-26 2020-12-02 Genzyme Corporation Fc variants with enhanced binding to fcrn and prolonged half-life
EP3870598A1 (en) * 2018-10-23 2021-09-01 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
TWI818236B (zh) * 2020-02-19 2023-10-11 美商聯合生物醫學公司 用於檢測、預防和治療新型冠狀病毒(covid-19)疾病的設計胜肽及蛋白質
WO2021170113A1 (zh) * 2020-02-29 2021-09-02 南京金斯瑞生物科技有限公司 ACE-2-Fc融合蛋白治疗冠状病毒的方法
WO2021183404A1 (en) 2020-03-07 2021-09-16 Planet Biotechnology, Inc. Ace2-fc fusion proteins for sars-cov-2 mitigation
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
CN113444710A (zh) 2020-03-25 2021-09-28 上海英脉德医疗科技有限公司 ACE2-Fc融合蛋白及其用途

Also Published As

Publication number Publication date
US20240018499A1 (en) 2024-01-18
EP4204091A2 (en) 2023-07-05
AU2021367988A1 (en) 2023-05-11
CA3193930A1 (en) 2022-05-05
JP2023547239A (ja) 2023-11-09
WO2022090469A2 (en) 2022-05-05
KR20230093483A (ko) 2023-06-27
AU2021367988A9 (en) 2023-07-13
WO2022090469A3 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
WO2021234160A3 (en) Ace2-fc fusion proteins and uses thereof
MX2023004933A (es) Proteinas de fusion de ace2 y usos de las mismas.
EP4257600A3 (en) Antibodies that target hiv gp120 and methods of use
MD3439672T2 (ro) Proteine F RVS de pre-fuziune solubile stabilizate pentru utilizare în profilixia infecţiilor cu RSV
WO2017151971A3 (en) METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
MX2018002183A (es) Composiciones y metodos para tratamiento del dolor.
MX2020009296A (es) Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso.
EA201692031A1 (ru) Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций
WO2022167816A3 (en) Antibodies
EA201992175A1 (ru) Композиции и способы, включающие пробиотические молекулы
WO2015067755A3 (en) Novel methods and antibodies for treating coagulapathy
WO2021236957A3 (en) Ace2 muteins and methods of using the same
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
WO2009114560A3 (en) Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
MX2021002909A (es) Vacunas de proteinas de fusion neumococicas.
JOP20210008A1 (ar) أنواع أبيراز مذابة، وطرق لاستخدامها
MX2022000433A (es) Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv.
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
MX2022002842A (es) Composiciones y metodos para el tratamiento del virus sincitial respiratorio.
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
WO2023006935A3 (en) Ace2 fusion proteins and uses thereof
MY192870A (en) Immunoglobulin single variable domain antibody against rsv prefusion f protein
MX2010005280A (es) Nuevos peptidos sinteticos sustituidos con arginina y su uso.